GC Biopharma

Expanded Access Policy for Sanfilippo Syndrome Type A
GC Biopharma is currently developing GC1130A, a potential enzyme replacement therapy for patients with Sanfilippo syndrome type A. We understand there may be interest in access to investigational product for patients outside of clinical trial. At this stage of clinical development, participation in a clinical study is the only way to gain access to GC Biopharma’s investigational product.